The BRIDGE Study - Bronchiectasis Research Involving Databases, Genomics and Endotyping
Bronchiectasis is a complex heterogeneous disorder. Treatment is challenging and many recent randomized controlled trials have been negative. It is believed that bronchiectasis as a broad diagnosis incorporates multiple different patient subgroups (also known as phenotypes) and molecular entities (referred to as endoty
| Condition(s) | Bronchiectasis Adult |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | Bronchiectasis is a complex heterogeneous disorder. Treatment is challenging and many recent randomized controlled trials have been negative. It is believed that bronchiectasis as a broad diagnosis incorporates multiple different patient subgroups (also known as phenotypes) and molecular entities (referred to as endotypes). This study aims to phenotype and endotype bronchiectasis during stable disease and exacerbations, to develop strategies for personalised medicine. Primary Objective To determine molecular endotypes of bronchiectasis which can guide response to treatment. Secondary Objectives 1. To determine molecular endotypes of stable bronchiectasis 2. To determine the causes and inflammatory profiles of bronchiectasis exacerbations 3. To validate candidate biomarkers of stable and ex |
| Who can participate | Inclusion Criteria: * A previous CT scan showing bronchiectasis along with compatible clinical syndrome of cough, sputum production and/or recurrent respiratory tract infections. * A primary diagnosis of bronchiectasis made by a respiratory physician * At the screening visit the individual will have been clinically stable for 4 weeks indicated by the lack of any treatment with antibiotics or corticosteroids for a pulmonary exacerbation in the previous 4 weeks. Exclusion Criteria: * Inability to give informed consent * \<18years of age * Patients with active tuberculosis * Treatment with antibiotics or corticosteroids for a pulmonary exacerbation in the previous 4 weeks * Bronchiectasis due to cystic fibrosis |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | University of Dundee |
| Locations | Dundee, United Kingdom |
| Start date | 2019-11-01 |
| NCT ID | NCT03791086 |
| Official listing | https://clinicaltrials.gov/study/NCT03791086 |